Novel hair removal system using advanced delivery technology
A cutting-edge system for hair degradation utilizing a novel delivery method to penetrate the lipid barrier of hair, enabling effective cleavage of disulphide bonds in keratin fibers. This offers a safer alternative to traditional depilatories like thioglycolic acid.
Overview
This innovative hair removal system overcomes the limitations of traditional depilatories like thioglycolic acid, which are known for their odorous scent, skin irritation, and potential toxicity. The proposed solution introduces a novel delivery mechanism that facilitates the passage of active hair-degrading molecules through the hair's outer lipid layer, effectively targeting and reducing the disulphide bonds within keratin fibers. This method promises a more efficient and safer approach to hair removal.
Technical specifications
The novel system addresses two primary challenges in hair degradation: the lipid layer, which acts as a barrier to hydrophilic molecules, and the disulphide bonds within keratin fibers that contribute to their mechanical strength. By developing a unique delivery system, hydrophilic active ingredients are transported through this lipid barrier to cleave cystine crosslinks inside the fiber. Ongoing research focuses on refining the formulation and improving the kinetics of this process to enhance efficacy and speed of the hair degradation.
Technology readiness level
Currently at TRL 3, the technology has demonstrated its foundational principles and requires further development to optimize the delivery rate of active ingredients. The next steps include refining the delivery formulation and measuring the kinetics of bond cleavage to advance the technology toward commercial readiness.
About Imperial College London
Imperial College London is a STEM‑focused public research university with a large postgraduate community and an entrepreneurial culture. Industry engages through the White City innovation district, where the university offers incubator and scale‑up labs, wet‑lab and prototyping facilities, co‑location with corporate R&D and startups, and a dedicated technology transfer office. Integration with a major NHS hospital system provides access to clinical cohorts, trials infrastructure, and translational expertise, while corporate relations streamline sponsored research and consortia. Research is supported by competitive funding from UK Research and Innovation councils, the National Institute for Health and Care Research, European programs, and major foundations.
delivered to your inbox.